Evercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public OfferingMarch 19, 2024 12:02 AM Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingMarch 18, 2024 11:58 PM Madrigal Pharma (MDGL) Announces Proposed $500M Public OfferingMarch 18, 2024 4:04 PM Madrigal Pharmaceuticals Announces Proposed Public OfferingMarch 18, 2024 4:04 PM Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)March 18, 2024 4:04 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $565 at Goldman SachsMarch 18, 2024 6:10 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $410 at UBSMarch 15, 2024 10:38 AM Midday movers: Adobe, Zillow fall; Micron risesMarch 15, 2024 8:52 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $400 at Jefferies, 'label hit our bull case'March 15, 2024 7:51 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at OppenheimerMarch 15, 2024 7:37 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $390 at TD CowenMarch 15, 2024 6:54 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $377 at Canaccord GenuityMarch 15, 2024 6:49 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'March 15, 2024 6:11 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at CitiMarch 15, 2024 3:49 AM Madrigal Pharma (MDGL) option IV into FDA approves Madrigal Pharmaceuticals' RezdiffraMarch 15, 2024 3:48 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $397 at JMP Securities, ' We had strong conviction'March 15, 2024 3:11 AM B.Riley Upgrades Madrigal Pharmaceuticals (MDGL) to NeutralMarch 15, 2024 3:10 AM